CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

Casgevy was approved at the same time as a rival treatment, bluebird bio’s Lyfgenia (lovotibeglogene autotemcel). Both treatments were given marketing authorisation for the same condition ...

Casgevy and Lyfgenia, the two cell-based gene therapies approved by the FDA, utilise the CRISPR/Cas9 genome editing technology. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR ...

The FDA approved Lyfgenia and Vertex Pharmaceuticals' (VRTX) Casgevy for the treatment of sickle cell disease in December 2023. Casgevy was co-developed with CRISPR Therapeutics (CRSP).

This latest gene therapy offering is Casgevy, which treats sickle cell disease and transfusion-dependent beta thalassemia, a blood disorder that reduces the production of hemoglobin.

Casgevy, which carries a $2.2 million list ... The spin-out left Bluebird with Zynteglo, Lyfgenia, and Skysona—all autologous hematopoietic stem cell-based gene therapies for severe genetic ...

Bluebird makes three gene therapies: Zynteglo for beta thalassemia, Lyfgenia for sickle cell disease and Skysona for cerebral adrenoleukodystrophy. The entire gene therapy field is facing tough ...

Bluebird said it would instead focus on the U.S., where it was readying for the approval of Zynteglo for beta thalassemia, Lyfgenia for sickle cell disease, as well as another therapy Skysona for ...